Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
91,837,471
-
Total 13F shares
-
2,904,420
-
Share change
-
-644,950
-
Total reported value
-
$6,302,000
-
Price per share
-
$2.17
-
Number of holders
-
12
-
Value change
-
-$2,229,327
-
Number of buys
-
8
-
Number of sells
-
10
Institutional Holders of Context Therapeutics Inc. - Common Stock (CNTX) as of Q1 2022
As of 31 Mar 2022,
Context Therapeutics Inc. - Common Stock (CNTX) was held by
12 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,904,420 shares.
The largest 10 holders included
SABBY MANAGEMENT, LLC, Affinity Asset Advisors, LLC, Worth Venture Partners, LLC, VANGUARD GROUP INC, Knoll Capital Management, LLC, Veritable, L.P., GEODE CAPITAL MANAGEMENT, LLC, swisspartners Ltd., RENAISSANCE TECHNOLOGIES LLC, and CITADEL ADVISORS LLC.
This page lists
12
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.